Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Total Non-Current Liabilities (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $101.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 13.93% year-over-year to $101.0 million, compared with a TTM value of $101.0 million through Sep 2025, down 13.93%, and an annual FY2024 reading of $110.5 million, up 37.36% over the prior year.
  • Total Non-Current Liabilities was $101.0 million for Q3 2025 at X4 Pharmaceuticals, down from $106.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $117.3 million in Q3 2024 and bottomed at $50.6 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is $82.6 million, with a median of $81.1 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities surged 53.6% in 2021, then decreased 13.93% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $51.9 million in 2021, then increased by 15.58% to $60.0 million in 2022, then surged by 34.05% to $80.5 million in 2023, then skyrocketed by 37.36% to $110.5 million in 2024, then fell by 8.65% to $101.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for XFOR at $101.0 million in Q3 2025, $106.5 million in Q1 2025, and $110.5 million in Q4 2024.